GSK Past Earnings Performance
Past criteria checks 4/6
GSK has been growing earnings at an average annual rate of 0.5%, while the Pharmaceuticals industry saw earnings declining at 1.7% annually. Revenues have been declining at an average rate of 3.1% per year. GSK's return on equity is 41.5%, and it has net margins of 16.2%.
Key information
0.5%
Earnings growth rate
-0.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | -3.1% |
| Return on equity | 41.5% |
| Net Margin | 16.2% |
| Next Earnings Update | 01 May 2024 |
Recent past performance updates
Recent updates
These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well
Apr 19
GSK's (LON:GSK) Solid Earnings Are Supported By Other Strong Factors
Feb 07We Think GSK (LON:GSK) Can Stay On Top Of Its Debt
Jan 17Insufficient Growth At GSK plc (LON:GSK) Hampers Share Price
Dec 27GSK (LON:GSK) Has Announced A Dividend Of £0.14
Nov 04Is GSK (LON:GSK) A Risky Investment?
Oct 04Revenue & Expenses BreakdownBeta
How GSK makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 30,328 | 4,928 | 9,156 | 5,823 |
| 30 Sep 23 | 29,652 | 6,078 | 8,965 | 5,671 |
| 30 Jun 23 | 29,334 | 5,373 | 8,767 | 5,436 |
| 31 Mar 23 | 29,085 | 4,455 | 8,469 | 5,282 |
| 31 Dec 22 | 29,324 | 4,461 | 8,179 | 5,153 |
| 30 Sep 22 | 29,024 | 3,387 | 7,803 | 4,905 |
| 30 Jun 22 | 27,822 | 3,505 | 7,429 | 4,741 |
| 31 Mar 22 | 26,731 | 4,013 | 7,104 | 4,691 |
| 31 Dec 21 | 24,696 | 3,316 | 6,784 | 4,627 |
| 30 Sep 21 | 26,359 | 3,567 | 7,436 | 4,640 |
| 30 Jun 21 | 28,378 | 3,934 | 8,285 | 4,566 |
| 31 Mar 21 | 30,164 | 4,983 | 9,176 | 4,622 |
| 31 Dec 20 | 24,354 | 4,873 | 7,041 | 4,397 |
| 30 Sep 20 | 34,259 | 6,371 | 10,719 | 4,537 |
| 30 Jun 20 | 34,998 | 6,679 | 11,085 | 4,648 |
| 31 Mar 20 | 35,183 | 5,380 | 10,993 | 4,519 |
| 31 Dec 19 | 33,754 | 4,645 | 10,962 | 4,405 |
| 30 Sep 19 | 33,052 | 4,561 | 10,103 | 4,266 |
| 30 Jun 19 | 31,759 | 4,427 | 9,575 | 4,065 |
| 31 Mar 19 | 31,260 | 3,904 | 9,488 | 3,887 |
| 31 Dec 18 | 30,821 | 3,623 | 9,500 | 3,799 |
| 30 Sep 18 | 30,263 | 1,862 | 9,234 | 3,755 |
| 30 Jun 18 | 30,014 | 1,656 | 9,185 | 3,696 |
| 31 Mar 18 | 30,024 | 1,035 | 9,143 | 3,890 |
| 31 Dec 17 | 30,186 | 1,532 | 9,424 | 3,925 |
| 30 Sep 17 | 30,133 | 2,335 | 9,303 | 3,886 |
| 30 Jun 17 | 29,832 | 1,931 | 9,260 | 3,863 |
| 31 Mar 17 | 29,044 | 1,676 | 9,017 | 3,604 |
| 31 Dec 16 | 27,889 | 912 | 8,852 | 3,550 |
| 30 Sep 16 | 26,589 | 301 | 8,553 | 3,370 |
| 30 Jun 16 | 25,174 | 31 | 8,025 | 3,226 |
| 31 Mar 16 | 24,530 | 615 | 8,097 | 3,163 |
| 31 Dec 15 | 23,923 | 8,422 | 9,232 | 3,560 |
| 30 Sep 15 | 23,823 | 9,809 | 7,810 | 3,218 |
| 30 Jun 15 | 23,342 | 9,672 | 7,425 | 3,227 |
| 31 Mar 15 | 23,015 | 10,177 | 7,261 | 3,258 |
| 31 Dec 14 | 23,006 | 2,756 | 8,246 | 3,450 |
| 30 Sep 14 | 23,726 | 4,184 | 7,209 | 3,333 |
| 30 Jun 14 | 24,590 | 4,752 | 7,673 | 3,359 |
| 31 Mar 14 | 25,647 | 5,143 | 7,820 | 3,478 |
| 31 Dec 13 | 26,505 | 5,436 | 8,480 | 3,923 |
| 30 Sep 13 | 26,401 | 3,823 | 7,514 | 3,430 |
| 30 Jun 13 | 26,418 | 3,959 | 7,820 | 3,543 |
Quality Earnings: GSK has a large one-off loss of £1.7B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: GSK's current net profit margins (16.2%) are higher than last year (15.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GSK's earnings have grown by 0.5% per year over the past 5 years.
Accelerating Growth: GSK's earnings growth over the past year (10.5%) exceeds its 5-year average (0.5% per year).
Earnings vs Industry: GSK earnings growth over the past year (10.5%) exceeded the Pharmaceuticals industry 3.8%.
Return on Equity
High ROE: Whilst GSK's Return on Equity (41.49%) is outstanding, this metric is skewed due to their high level of debt.